NCT03212937View on ClinicalTrials.gov

Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

July 1, 2016

Primary Completion Date

November 30, 2020

Study Completion Date

November 30, 2020

Conditions
Peripheral T-cell Lymphoma
Interventions
DRUG

Selinexor

Oral KPT-330 is administered on Day 3, 5, and 7 of each 21-day cycle. Starting dose is 40mg will be adjusted according to toxicity

DRUG

ICE Chemotherapy

"IV Ifosfamide 5g/m\^2 on Day 2 (inpatient) or D1 (outpatient) of each 21-day cycle~IV Carboplatin AUC 5 on Day 2 (inpatient) or D1-3 (outpatient) of each 21-day cycle~IV Etoposide 100 mg/m\^2 on Days 1-3 of each 21-day cycle"

Trial Locations (1)

169610

National Cancer Centre Singapore, Singapore

All Listed Sponsors
lead

National Cancer Centre, Singapore

OTHER

NCT03212937 - Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell Lymphoma | Biotech Hunter | Biotech Hunter